1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31970
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLoft, Matthew-
dc.contributor.authorLok, Sheau Wen-
dc.contributor.authorDe Boer, Richard-
dc.contributor.authorMalik, Laeeq-
dc.contributor.authorGreenberg, Sally-
dc.contributor.authorYeo, Belinda-
dc.contributor.authorAnton, Angelyn-
dc.contributor.authorNottage, Michelle-
dc.contributor.authorWong, Vanessa-
dc.contributor.authorNott, Louise-
dc.contributor.authorCollins, Ian M-
dc.contributor.authorTorres, Javier-
dc.contributor.authorBarnett, Frances-
dc.contributor.authorLombard, Janine M-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorGately, Lucy-
dc.date2023-
dc.date.accessioned2023-01-24T03:01:19Z-
dc.date.available2023-01-24T03:01:19Z-
dc.date.issued2023-02-
dc.identifier.citationBreast Cancer Research and Treatment 2023; 198(1)en_US
dc.identifier.issn1573-7217-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/31970-
dc.description.abstractDual anti-HER2 targeted therapy and chemotherapy is the current first-line standard of care for HER2 + metastatic breast cancer (MBC), with endocrine therapy (ET) the backbone of treatment in hormone receptor positive (HR +) disease. The potential ET benefit in HER2 + /HR + patients is unknown as pivotal dual anti-HER2 clinical trials precluded ET use.en_US
dc.language.isoeng-
dc.subjectEndocrine therapyen_US
dc.subjectHER2en_US
dc.subjectHormone receptor-positiveen_US
dc.subjectMetastatic breast canceren_US
dc.titleAddition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBreast Cancer Research and Treatmenten_US
dc.identifier.affiliationDivision of Personalised Oncology, Walter and Eliza Hall, 1G Royal Pde, Parkville, VIC, 3052, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Canberra Hospital, Garran, ACT, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Western Health, Footscray, VIC, Australia.en_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.affiliationDivision of Personalised Oncology, Walter and Eliza Hall, 1G Royal Pde, Parkville, VIC, 3052, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Royal Brisbane Hospital, Herston, QLD, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, South West Healthcare, Warrnambool, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Northern Hospital, Epping, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Newcastle Private Hospital, New Lambton Heights, NSW, Australia.en_US
dc.identifier.doi10.1007/s10549-022-06856-1en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3267-4520en_US
dc.identifier.pubmedid36624321-
local.name.researcherWong, Vanessa
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMedical Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

60
checked on Dec 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.